North Star Investment Management’s Esperion Therapeutics ESPR Stock Holding History

North Star Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$123K	Hold	45,000	–	–	0.01%	570
2025 Q4	$167K	Buy	45,000 +10,000	+29%	+$32.3K	0.01%	469
2025 Q3	$92.8K	Buy	35,000 +10,000	+40%	+$19.3K	0.01%	540
2025 Q2	$24.6K	Buy	+25,000	New	+$25K	﹤0.01%	753
2021 Q4	–	Sell	-100	Closed	-$1K	–	1194
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	1071
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	1015
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	946
2020 Q4	$3K	Hold	100	–	–	﹤0.01%	916
2020 Q3	$4K	Hold	100	–	–	﹤0.01%	874
2020 Q2	$5K	Hold	100	–	–	﹤0.01%	821
2020 Q1	$3K	Buy	+100	New	+$5.28K	﹤0.01%	882
2019 Q2	–	Sell	-70	Closed	-$3K	–	552
2019 Q1	$3K	Hold	70	–	–	﹤0.01%	973
2018 Q4	$3K	Hold	70	–	–	﹤0.01%	962
2018 Q3	$3K	Hold	70	–	–	﹤0.01%	988
2018 Q2	$3K	Hold	70	–	–	﹤0.01%	1001
2018 Q1	$5K	Hold	70	–	–	﹤0.01%	936
2017 Q4	$5K	Buy	+70	New	+$3.77K	﹤0.01%	912

Other funds holding ESPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

North Star Investment Management's ESPR Position: Q1 2026 in Review

North Star Investment Management held its Esperion Therapeutics (ESPR) position steady in Q1 2026 at 45,000 shares worth $123K. The position accounts for 0.01% of the portfolio, ranked #570.

North Star Investment Management first reported a position in ESPR in Q4 2017 and has held it in 17 quarters since. The position peaked at $167K in Q4 2025. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

North Star Investment Management held 45,000 shares of Esperion Therapeutics worth $123K as of Q1 2026.
North Star Investment Management left its Esperion Therapeutics share count unchanged in Q1 2026.
Esperion Therapeutics made up 0.01% of North Star Investment Management's portfolio in Q1 2026, its #570 holding.
North Star Investment Management first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 17 quarters since.
North Star Investment Management's Esperion Therapeutics position peaked at $167K in Q4 2025.
205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on North Star Investment Management's 13F filing for Q1 2026, filed 23 Apr 2026.